Abstracts Archive - Page 277 of 2607 - ACR Meeting Abstracts

Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Ivanna Romankevych¹, Nora Singer², Kaliyani Marathe³, Angela Merritt¹, Ekemini Ogbu⁴, Chen Chen⁵, Megan Quinlan-Waters¹, Kathleen Pelletier⁶, Haihong Shi⁶, Xiaoxing Wang⁶, Bin Huang⁷ and hermine brunner⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cin, OH, ⁶Pfizer Inc, Groton, CT, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…
Abstract Number: 0601 • ACR Convergence 2024
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Peter C. Taylor¹, Lihi Eder², Yael Klionsky³, Fabian Proft⁴, Thomas Iyile⁵, Erin Mancl⁶, Priscila Magalhaes Reis Nakasato⁷, Xiaolan Ye⁸, Limei Zhou⁶ and Philip Mease⁹, ¹University of Oxford, Oxford, United Kingdom, ²University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵AbbVie Inc., hyattsville, MD, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., Randolph, NJ, ⁸AbbVie Inc., Mettawa, IL, ⁹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0551 • ACR Convergence 2024
Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
Dafne Capelusnik¹, Anna Molto², Clementina López Medina³, Desiree van der Heijde⁴, Robert Landewé⁵, Maxime Dougados⁶, Joachim Sieper⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
Abstract Number: 0559 • ACR Convergence 2024
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Diego Benavent¹, Victor Fanjul², Sytske Anne Bergstra³, Floris van Gaalen⁴, Maxime Dougados⁵, Umut Kalyoncu⁶, Denis Poddubnyy⁷, Clementina López Medina⁸, Konstantinos Parperis⁹, David Vega-Morales¹⁰, Desiree van der Heijde¹¹ and Victoria Navarro Compán¹², ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²Savana Research, Madrid, ³LUMC, Leiden, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands, ⁵Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁶Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁷Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁸Reina Sofia University Hospital, Cordoba, Spain, ⁹University of Cyprus Medical School, Nicosia, Cyprus, ¹⁰Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, ¹¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
Abstract Number: 0609 • ACR Convergence 2024
The Mediating Role of Trust in Usual Rheumatologists on the Relationship Between Multidimensional Health Literacy and Medication Adherence Among Japanese Systemic Lupus Erythematosus Patients
Nao Oguro¹, Nobuyuki Yajima², Yuichi Ishikawa³, Natsuki Sakurai⁴, Chiharu Hidekawa⁴, Takanori Ichikawa⁵, Dai Kishida⁵, Keigo Hayashi⁶, Kenta Shidahara⁷, Yoshia Miyawaki⁸, Ryusuke Yoshimi⁹, Kenei Sada¹⁰, Yasuhiro Shimojima⁵ and Noriaki Kurita¹¹, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Stem Cell and Immune Regulation,Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ⁵Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ⁶Brigham and Women’s Hospital, Brookline, MA, ⁷"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁸Center for Innovative Clinical Medicine, Okayama University Hospital Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Yokohama, Kanagawa, Japan, ¹⁰Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ¹¹"Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University Department of Innovative Research and Education for Clinicians and Trainees (DiRECT) Fukushima Medical University Hospital", Fukushima, Fukushima, Japan
Background/Purpose: Maintaining medication adherence is crucial for improving health outcomes among patients with systemic lupus erythematosus, as they require life-long hospital visits and medications. Patients'…
Abstract Number: 0652 • ACR Convergence 2024
Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis
Gamze Kemec¹, Sibel Varelci², Erdem Gurel², Isın Kılıcaslan³, Yasemın özlük³, Yasemın Yalcınkaya⁴, Ahmet Gul⁵, Murat Inanc⁶ and bahar Artım Esen⁴, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Pathology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, ⁶Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Relapses are correlated with increased hospitalizations, poor renal outcomes, morbidity and mortality. We aim to investigate the incidence, predictive factors and outcomes related to…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Maureen Dubreuil¹, Marina Magrey², Kathrin Haeffs³, Evgueni Ivanov⁴ and Julie Gandrup Horan⁵, ¹Section of Rheumatology, Boston University School of Medicine, Boston, MA, ²Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Bulle, Switzerland, ⁵UCB Pharma, Slough, United Kingdom
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Takehiro HIrayama¹, Kohei Tsujimoto², Kayoko Kaneko³, Sakiko Isojima⁴, Kunihiro Ichinose⁵, Yasunori Iwata⁶, Kenji Oku⁷, Kenei Sada⁸, Yoshiya Tanaka⁹, Ayako Nakajima¹⁰, Keishi Fujio¹¹, Masakazu Matsushita¹², Takako Miyamae¹³, Atsuko Murashima³ and Atsushi Kumanogoh¹⁴, ¹Osaka university, Ibaraki City, Japan, ²Osaka University, Toyonaka, Osaka, Osaka, Japan, ³National Center for Child Health and Development, Setagaya, Tokyo, Japan, ⁴Showa Univeristy, Shinagawa, Tokyo, Japan, ⁵Shimane University, Izumo, Shimane, Japan, ⁶Kanazawa University, kanazawa, Japan, ⁷Kitazato University, Sagamihara, Kanagawa, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ¹¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., TOKYO, Japan, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Osaka University, Osaka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…
Abstract Number: 0590 • ACR Convergence 2024
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Sofia Ramiro¹, Corine Gaillez², Uta Kiltz³, Lianne S Gensler⁴, Chaitali Pisal⁵, Juergen Braun⁶ and Alexis Ogdie⁷, ¹Leiden University Medical Center, Bunde, Netherlands, ²Novartis Pharma AG, Basel, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Novartis Healthcare Private Limited, Hyderabad, India, ⁶Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].